Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Analysis of RECOVERY trial (n=11,340) found no benefit for colchicine over usual care in adults hospitalised with COVID-19 for 28-day mortality, duration of hospital stay or risk of progressing to invasive mechanical ventilation or death, with no benefit in any patient subgroup.

SPS commentary:

It was reported earlier in the year that recruitment to this arm of the RECOVEY trial had been closed, after a preliminary analysis found no significant difference in 28-day mortality versus usual care.

The Lancet Respiratory Medicine